Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers, which affect approximately 30% of human cancers; its pip…
HQ: San Diego, CA, United States of Americawww.erasca.com
USD15.66-0.76%vs prev. close
Performance
1W
+18.91%
1M
+6.77%
3M
-11.65%
1Y
+495.47%
YTD
+324.19%
Valuation
P/E
—
EPS TTM
-0.95
Dividend yield
—
Size and risk
Market cap
$5.5B
Beta
0.65
Price history
ERAS price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Erasca
ERAS
Biotechnology
Mkt cap (USD bn)
5.5
P/E
—
Div yld
—
1W
+18.9%
1M
+6.8%
3M
-11.7%
6M
+52.2%
1Y
+495.5%
YTD
+324.2%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Erasca
ERAS
Biotechnology
5.5
—
—
+18.9%
+6.8%
-11.7%
+52.2%
+495.5%
+324.2%
Subscribe to Equity Analytics to compare ERAS with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.